Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma

Journal of Clinical Oncology

Volumn 24, Issue 16, 2006, Pages 2505-2512

  Ratain, Mark J ^a   Eisen, Tim ^a   Stadler, Walter M ^a   Flaherty, Keith T ^a   Kaye, Stan B ^a   Rosner, Gary L ^a   Gore, Martin ^a   Desai, Apurva A ^a   Patnaik, Amita ^a   Xiong, Henry Q ^a   Rowinsky, Eric ^a   Abbruzzese, James L ^a   Xia, Chenghua ^a   Simantov, Ronit ^a   Schwartz, Brian ^a   O'Dwyer, Peter J ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SORAFENIB; ANTINEOPLASTIC AGENT; BENZENESULFONIC ACID DERIVATIVE; PYRIDINE DERIVATIVE;

ALOPECIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DESQUAMATION; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DRY SKIN; DYSPNEA; EDEMA; FATIGUE; FEMALE; FEVER; FLUSHING; HAND FOOT SYNDROME; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERGLYCEMIA; HYPERTENSION; HYPERURICEMIA; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MYALGIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; TUMOR GROWTH; WEIGHT REDUCTION; ADULT; AGED; DRUG ADMINISTRATION; KIDNEY TUMOR; MIDDLE AGED; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PATHOLOGY; PHASE 2 CLINICAL TRIAL; SURVIVAL; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PYRIDINES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 33744984843     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.03.6723     Document Type: Article

References (30)

1. Wilhelm S, Chien DS: BAY 43-9006: Preclinical data. Curr Pharm Des 8:2255-2257, 2002
2. Hilger RA, Scheulen ME, Strumberg D: The Ras-Raf-MEK-ERK pathway in the treatment of cancer. Onkologie 25:511-518, 2002
3. Wilhelm SM, Carter C, Tang L, et al: BAY 43-9006 exhibits broad spectrum oral anti-tumor activity and targets the Raf/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64:7099-7109, 2004
4. Awada A, Hendlisz A, Gil T, et al: Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br J Cancer 92:1855-1861, 2005
5. Clark JW, Eder JP, Ryan D, et al: The safety and pharmacokinetics of the multi-targeted tyrosine kinase inhibitor (including Raf kinase and VEGF kinase), BAY 43-9006, in patients with advanced, refractory solid tumors. Clin Cancer Res 11:5472-5480, 2005
6. Moore MJ, Hirte HW, Siu L, et al: Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. Ann Oncol 16:1688-1694, 2005
7. Strumberg D, Richly H, Hilger RA, et al: Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 23:965-972, 2005
8. Ratain MJ, Eckhardt SG: Phase II studies of modern drugs directed against new targets: If you are fazed, too, then resist RECIST. J Clin Oncol 22:4442-4445, 2004
9. Amery W, Dony J: A clinical trial design avoiding undue placebo treatment. J Clin Pharmacol 15:674-679, 1975
10. Chiron C, Dulac O, Gram L: Vigabatrin withdrawal randomized study in children. Epilepsy Res 25:209-215, 1996
11. Cibere J, Kopec JA, Thorne A, et al: Randomized, double-blind, placebo-controlled glucosamine discontinuation trial in knee osteoarthritis. Arthritis Rheum 51:738-745, 2004
12. Gotzsche PC, Hansen M, Stoltenberg M, et al: Randomized, placebo controlled trial of withdrawal of slow-acting antirheumatic drugs and of observer bias in rheumatoid arthritis. Scand J Rheumatol 25:194-199, 1996
13. Holmes C, Wilkinson D, Dean C, et al: The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease. Neurology 63:214-219, 2004
14. Kopec JA, Abrahamowicz M, Esdaile JM: Randomized discontinuation trials: Utility and efficiency. J Clin Epidemiol 46:959-971, 1993
15. Uretsky BF, Young JB, Shahidi FE, et al: Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: Results of the PROVED trial - PROVED Investigative Group. J Am Coll Cardiol 22:955-962, 1993
16. Rosner GL, Stadler W, Ratain MJ: Randomized discontinuation design: Application to cytostatic anti-neoplastic agents. J Clin Oncol 20:4478-4484, 2002
17. Stadler WM, Rosner G, Small E, et al: Successful implementation of the randomized discontinuation trial design: An application to the study of the putative antiangiogenic agent carboxyaminoimidazole in renal cell carcinoma - CALGB 69901. J Clin Oncol 23:3726-3732, 2005
18. Bos JL: Ras oncogenes in human cancer: A review. Cancer Res 49:4682-4689, 1989
19. Davies H, Bignell GR, Cox C, et al: Mutations of the BRAF gene in human cancer. Nature 417:949-954, 2002
20. Miller AB, Hoogstraten B, Staquet M, et al: Reporting results of cancer treatment. Cancer 47: 207-214, 1981
21. Escudier B, Szczylik C, Eisen T, et al: Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). J Clin Oncol 23:1093s, 2005 (suppl; abstr 4510)
22. Amin MB, Amin MB, Tamboli P, et al: Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: An experience of 405 cases. Am J Surg Pathol 26:281-291, 2002
23. Yang JC, Haworth L, Sherry RM, et al: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349:427-434, 2003
24. Pacey SC, Ratain MJ, O'Dwyer PO, et al: Phase II antitumor activity of BAY 43-9006, a novel Raf kinase and VEGFR inhibitor, in patients with sarcoma enrolled in a randomized discontinuation study. Eur J Cancer 2:114, 2004 (abstr)
25. Abou-Alfa GK, Schwartz L, Ricci S, et al: Phase II study of BAY 43-9006 in patients with advanced hepatocellular carcinoma (HCC). Eur J Cancer 2:16, 2004 (abstr)
26. Flaherty KT, Brose M, Schuchter L, et al: Phase I/II trial of BAY 43-9006, carboplatin and paclitaxel demonstrates preliminary antitumor activity in the expansion cohort of patients with metastatic melanoma. J Clin Oncol 23:711s, 2004 (suppl; abstr 7507)
27. Farr NL: Questioning placebo controls. Science 288:1747, 2000
28. Lavin PT: An alternative model for the evaluation of antitumor activity. Cancer Clinical Trials 4:451-457, 1981
29. Motzer RJ, Mazumdar M, Bacik J, et al: Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17:2530-2540, 1999
30. Motzer RJ, Bacik J, Schwartz LH, et al: Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 22:454-463, 2004